Summary: Children with TS, besides having vocal and motor tics, may be at risk for behavioral and neuropsychological disturbances, which may be associated with TS itself or related to the pharmacologic agents used in treatment. With the approval of pimozide by the FDA, patients now have a choice among dopamine blocking agents, with preliminary studies suggesting that pimozide has comparable efficacy with haloperidol for symptomatic relief of TS with less adverse neuropsychiatric side effects. This study is designed as a comparison of pimozide and haloperidol in children ages 6 – 16, with particular attention to the effects of medication on learning and memory as well as-on TS symptomatology. The study is unique in its attempt to document plasma levels of pimozide or haloperidol which may be associated with therapeutic or toxic consequences. R. Sallee, M.D., Assistant Professor of Child Psychiatry Western Psychiatric Institute and Clinic University of Pittsburgh, Pittsburgh, PA A recent Physician Scientist Award recipient of the National Institute of Mental Health and a Ph.D. candidate in Pharmacology at the University of Pittsburgh School of Medicine, Dr. Sallee has four years of prior experience in clinical Pharmacology with research interests in pediatric psychopharmacology. Award: $15,000 Tourette Association of America, Inc. – Research Grant Award 1985